Form 51-102F3
Material Change Report

1. Name and Address of Company

Resverlogix Corp. ("Resverlogix")
202, 279 Midpark Way SE
Calgary, AB T2X 1M2

2. Date of Material Change

September 3, 2013

3. News Release

September 3, 2013 via CNW Group

4. Summary of Material Change

Resverlogix announced the Full Analysis Set (FAS) data from 281 treated patients in its Phase 2b ASSURE clinical trial evaluating RVX-208 using intravascular ultrasound (IVUS) in high-risk cardiovascular patients. Current findings show that the below median HDL (<39 mg/dL) baseline population consisted of 92 patients who were taking either Rosuvastatin (Crestor®) or Atorvastatin (Lipitor®) together with RVX-208. Those patients taking Rosuvastatin and RVX-208 had a highly statistically significant Percent Atheroma Volume (PAV) plaque regression of -1.43% with probability value of $p<0.002$. This PAV regression exceeded the trial's pre-specified PAV endpoint (-0.6%) by more than two-fold. But those patients taking Atorvastatin (Lipitor®) together with RVX-208 had a PAV plaque progression of +0.19% with a non-significant probability value.

5. Full Description of Material Change

Resverlogix announced the Full Analysis Set (FAS) data from 281 treated patients in its Phase 2b ASSURE clinical trial evaluating RVX-208 using intravascular ultrasound (IVUS) in high-risk cardiovascular patients. Current findings show that the below median HDL (<39 mg/dL) baseline population consisted of 92 patients who were taking either Rosuvastatin (Crestor®) or Atorvastatin (Lipitor®) together with RVX-208. Those patients taking Rosuvastatin and RVX-208 had a highly statistically significant Percent Atheroma Volume (PAV) plaque regression of -1.43% with probability value of $p<0.002$. This PAV regression exceeded the trial's pre-specified PAV endpoint (-0.6%) by more than two-fold. But those patients taking Atorvastatin (Lipitor®) together with RVX-208 had a PAV plaque progression of +0.19% with a non-significant probability value. The synergistic effect of the Rosuvastatin and RVX-208 combination is the basis for two recent provisional patent applications by Resverlogix.

Ongoing analysis is providing important insights into why the ASSURE topline results, reported previously on June 27, 2013, did not meet its primary endpoint of PAV change of -0.6%. Third party analysis of the ASSURE data showed that Rosuvastatin enhanced the actions of RVX-208 leading to synergistic treatment effects on PAV.

The responder population (i.e. HDL <39 mg/dL taking Rosuvastatin and RVX-208) exceeded the primary endpoint and also surpassed secondary endpoints reflecting

regression in coronary atherosclerosis. These measures included total atheroma volume (TAV) and changes in the 10 mm most diseased segment of the coronary arteries, we noted marked regression versus baseline of -12.3 mm^3 ($p< 0.0001$) and -4.3 mm^3 ($p<0.0001$), respectively. Other secondary endpoints assessed in this population were biomarkers of reverse cholesterol transport (RCT), including: HDLc, ApoA-I and large HDL particles which increased by 18.2% ($p<0.0001$), 16.4% ($p<0.0001$) and 74.7% ($p<0.0001$), respectively, vs. baseline.

6. Reliance of subsection 7.1(2) of National Instrument 51-102

N/A

7. Omitted Information

N/A

8. Executive Officer

Donald J. McCaffrey, President & CEO
Telephone: (403) 254-9252

9. Date of Report

September 3, 2013